Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK1 | Q15118 | 4/20 | 0.49 |
| ▸ | USP2 | O75604 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 2/20 | 0.41 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.40 |
| ▸ | IL1B | P01584 | 1/20 | 0.39 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.39 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.38 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.38 |
| ▸ | CTSD | P07339 | 1/20 | 0.35 |
| ▸ | CTSL | P07711 | 1/20 | 0.35 |
| ▸ | CTSB | P07858 | 1/20 | 0.35 |
| ▸ | CTSS | P25774 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL305110 | 1.00 | PDK1 (0.49) | PDK1USP2SMN1; SMN2RECQLATM | |
| SCHEMBL1184919 | 1.00 | PDK1 (0.49) | PDK1USP2SMN1; SMN2RECQLATM | |
| SCHEMBL31148538 | 0.91 | SMN1; SMN2 (0.43) | PDK1USP2SMN1; SMN2RECQLATM | |
| SCHEMBL30789316 | 0.91 | SMN1; SMN2 (0.43) | PDK1USP2SMN1; SMN2RECQLATM | |
| SCHEMBL4223343 | 0.88 | USP2 (0.46) | PDK1USP2SMN1; SMN2RECQLATM | |
| SCHEMBL11995203 | 0.88 | USP2 (0.46) | PDK1USP2SMN1; SMN2RECQLATM | |
| SCHEMBL18914800 | 0.88 | USP2 (0.46) | PDK1USP2SMN1; SMN2RECQLATM | |
| SCHEMBL14417217 | 0.88 | USP2 (0.49) | PDK1USP2SMN1; SMN2RECQLATM | |
| SCHEMBL3641031 | 0.88 | USP2 (0.49) | PDK1USP2SMN1; SMN2RECQLATM | |
| SCHEMBL20371626 | 0.88 | USP2 (0.49) | PDK1USP2SMN1; SMN2RECQLATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 148 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3959211-B1 | 4H-PYRROLO[3,2-C]PYRIDIN-4-ONE COMPOUNDS | BAYER AG (DE) | 2026-02-18 | — | — | EP | disclosed |
| EP-4689155-A1 | USE OF INHIBITORS TO INCREASE EFFICIENCY OF CRISPR/CAS INSERTIONS | Astrazeneca AB (SE) | 2026-02-11 | — | — | EP | disclosed |
| US-12492197-B2 | 3,5-disubstituted pyrazole compounds as kinase inhibitors and uses thereof | Impact Therapeutics (Shanghai), Inc (CN) | 2025-12-09 | — | — | US | disclosed |
| EP-4630410-A1 | POLQ INHIBITORS | Astrazeneca AB (SE) | 2025-10-15 | — | — | EP | disclosed |
| US-12414954-B2 | POLQ inhibitors | ASTRAZENECA AB (SE) | 2025-09-16 | — | — | US | disclosed |
| US-20250195530-A1 | POLQ INHIBITORS | ASTRAZENECA AB (SE) | 2025-06-19 | — | — | US | disclosed |
| US-20250171402-A1 | Potent and Selective Human Neuronal Nitric Oxide Synthase Inhibitors | UNIV NORTHWESTERN (US) | 2025-05-29 | — | — | US | disclosed |
| US-20250136599-A1 | 4H-PYRROLO[3,2-C]PYRIDIN-4-ONE COMPOUNDS | BAYER AKTIENGESELLSCHAFT (DE) | 2025-05-01 | — | — | US | disclosed |
| US-20250127801-A1 | BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND USES THEREOF | GILEAD SCIENCES, INC. | 2025-04-24 | — | — | US | disclosed |
| EP-3853234-B1 | FUSED TRICYCLIC RING DERIVATIVES AS SRC HOMOLOGY-2 PHOSPHATASE INHIBITORS | NIKANG THERAPEUTICS INC (US) | 2025-04-23 | — | — | EP | disclosed |
| WO-2006105262-A1 | HETEROARYL UREA DERIVATIVES USEFUL FOR INHIBITING CHKl | ICOS CORPORATION (US) | 2006-10-05 | — | — | WO | disclosed |
| EP-1699798-A2 | DI-SUBSTITUTED PYRROLOTRIAZINE COMPOUNDS | Bristol-Myers Squibb Company (US) | 2006-09-13 | — | — | EP | disclosed |
| US-7064203-B2 | Di-substituted pyrrolotriazine compounds | BRISTOL MYERS SQUIBB COMPANY (US) | 2006-06-20 | — | — | US | disclosed |
| US-20050222153-A1 | C-6 modified indazolylpyrrolotriazines | VITE GREGORY D | 2005-10-06 | — | — | US | disclosed |
| US-20050197339-A1 | Di-substituted pyrrolotrizine compounds | BRISTOL-MYERS SQUIBB COMPANY | 2005-09-08 | — | — | US | disclosed |
| WO-2005065266-A2 | DI-SUBSTITUTED PYRROLOTRIAZINE COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-07-21 | — | — | WO | disclosed |
| US-6916815-B2 | C-6 modified indazolylpyrrolotriazines | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-07-12 | — | — | US | disclosed |
| US-20040142931-A1 | C-6 modified indazolylpyrrolotriazines | BRISTOL-MYERS SQUIBB COMPANY | 2004-07-22 | — | — | US | disclosed |
| US-6221865-B1 | INHIBITORS OF PROTEIN FARNESYLTRANSFERASE AND PROTEIN GERANYLGERANYLTRANSFERASE. | UNIVERSITY OF PITTSBURGH | 2001-04-24 | — | — | US | disclosed |
| WO-1998050030-A1 | INHIBITORS OF PROTEIN ISOPRENYL TRANSFERASES | UNIVERSITY OF PITTSBURGH (US) | 1998-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12492197-B2 | 3,5-disubstituted pyrazole compounds as kinase inhibitors and uses thereof | CHEK1, CHEK2, CCNK | PDK1 316/4885USP2 1684/4885SMN1; SMN2 4202/4885 |
| US-20050222153-A1 | C-6 modified indazolylpyrrolotriazines | ERBB2, ERBB4, EGFR | PDK1 890/4885USP2 4240/4885SMN1; SMN2 4572/4885 |
| US-12414954-B2 | POLQ inhibitors | POLQ, POLG, POLB | PDK1 2002/4885USP2 3499/4885SMN1; SMN2 2586/4885 |
| US-20050197339-A1 | Di-substituted pyrrolotrizine compounds | ERBB2, ERBB4, EGFR | PDK1 145/4885USP2 4352/4885SMN1; SMN2 4784/4885 |
| US-20250136599-A1 | 4H-PYRROLO[3,2-C]PYRIDIN-4-ONE COMPOUNDS | CYP4B1, CYP2C19, PAH | PDK1 179/4885USP2 4225/4885SMN1; SMN2 407/4885 |
| US-20250127801-A1 | BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND USES THEREOF | SDHA, SDHB, DPYD | PDK1 128/4885USP2 3590/4885SMN1; SMN2 2987/4885 |
| US-20250171402-A1 | Potent and Selective Human Neuronal Nitric Oxide Synthase Inhibitors | NOS2, NOS1, NOS3 | PDK1 1744/4885USP2 2470/4885SMN1; SMN2 71/4885 |
| US-20250195530-A1 | POLQ INHIBITORS | POLQ, POLG, POLB | PDK1 2002/4885USP2 3499/4885SMN1; SMN2 2586/4885 |
| US-20040142931-A1 | C-6 modified indazolylpyrrolotriazines | ERBB2, ERBB4, EGFR | PDK1 907/4885USP2 4320/4885SMN1; SMN2 4567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.